C/EBPα mutations in acute myeloid leukaemias

Nature Reviews Cancer

Volumn 4, Issue 5, 2004, Pages 394-400

  Nerlov, Claus ^a  

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY EMBL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER INHIBITION; CELL CYCLE; GENE FUNCTION; GENE MUTATION; HUMAN; LEUKEMOGENESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; ACUTE DISEASE; ANIMAL; GENETICS; MUTATION; MYELOID LEUKEMIA;

ACUTE DISEASE; ANIMALS; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; HUMANS; LEUKEMIA, MYELOID; MUTATION;

EID: 2342544921     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1363     Document Type: Review

References (57)

1. Tenen, D. G. Disruption of differentiation in human cancer: AML shows the way. Nature Rev. Cancer 3, 89-101 (2003).
2. Wang, N. D. et al. Impaired energy homeostasis in C/EBPα knockout mice. Science 269, 1108-1112 (1995). This paper demonstrates the requirement for C/EBPα during white-fat adipogenesis.
3. Zhang, D. E. et al. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein α-deficient mice. Proc. Natl Acad. Sci. USA 94, 569-574 (1997). This paper provided the first demonstration of a block In granulopoiesis in the absence of the C/EBPα protein.
4. Freytag, S. O., Paielli, D. L. & Gilbert, J. D. Ectopic expression of the CCAAT/enhancer-binding protein α promotes the adipogenic program in a variety of mouse fibroblastic cells. Genes Dev. 8, 1654-1663 (1994).
5. Radomska, H. S. et al. CCAAT/enhancer binding protein α is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol. Cell. Biol. 18, 4301-4314 (1998).
6. Nerlov, C., McNagny, K. M., Doderlein, G., Kowenz-Leutz, E. & Graf, T. Distinct C/EBP functions are required for eosinophil lineage commitment and maturation. Genes Dev. 12, 2413-2423 (1998).
7. Lin, F. T., MacDougald, O. A., Diehl, A. M. & Lane, M. D. A 30-kDa alternative translation product of the CCAAT/enhancer binding protein α message: transcriptional activator lacking antimitotic activity. Proc. Natl Acad. Sci. USA 90, 9606-9610 (1993).
8. Calkhoven, C. F., Muller, C. & Leutz, A. Translational control of C/EBPα and C/EBPβ isoform expression. Genes Dev. 14, 1920-1932 (2000). An elegant demonstration of how translational control can alter the function of a transcription factor by selectively including or excluding functional domains in response to extracellular signalling.
9. Rosenwald, I. B., Rhoads, D. B., Callanan, L. D., Isselbacher, K. J. & Schmidt, E. V. Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2α in response to growth induction by c-myc. Proc. Natl Acad. Sci. USA 90, 6175-6178 (1993).
10. D'Alo', F. et al. The amino terminal and E2F interaction domains are critical for C/EBPα-mediated induction of granulopoietic development of hematopoietic cells. Blood 102, 3163-3171 (2003).
11. Lazaris-Karatzas, A., Montine, K. S. & Sonenberg, N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 345, 544-547 (1990).
12. Pabst, T. et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia. Nature Genet. 27, 253-270 (2001). The first demonstration of mutations in a lineage-specific transcriptional regulator in patients with AML.
13. Gombart, A. F. et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein α in myelodysplastic syndromes and acute myeloid leukemias. Blood 99, 1332-1340 (2002).
14. Preudhomme, C. et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 100, 2717-2723 (2002).
15. Van Waalwijk Van Doorn-Khosrovani, S. B. et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol. J. 4, 31-40 (2003).
16. Kaeferstein, A. et al. The emergence of a C/EBPα mutation in the clonal evolution of MDS towards secondary AML. Leukemia 17, 343-349 (2003).
17. Snaddon, J. et al. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosom. Cancer 37, 72-78 (2003).
18. Asou, H. et al. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPα gene. Genes Chromosom. Cancer 36, 167-174 (2003).
19. Pabst, T. et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia. Nature Med. 7, 444-451 (2001).
20. Cilloni, D. et al. Down-modulation of the C/EBPα transcription factor in core binding factor acute myeloid leukemias. Blood 102, 2705-2706 (2003).
21. Perrotti, D. et al. BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2. Nature Genet. 30, 48-58 (2002).
22. Friedman, A. D., Landschulz, W. H. & McKnight, S. L. CCAAT/enhancer binding protein activates the promoter of the serum albumin gene in cultured hepatoma cells. Genes Dev. 3, 1314-1322 (1989).
23. Christy, R. J. et al. Differentiation-induced gene expression in 3T3-L1 preadipocytes: CCAAT/enhancer binding protein interacts with and activates the promoters of two adipocyte-specific genes. Genes Dev. 3, 1323-1335 (1989).
24. Tenen, D. G., Hromas, R., Licht, J. D. & Zhang, D. E. Transcription factors, normal myeloid development, and leukemia. Blood 90, 489-519 (1997).
25. McNagny, K. M., Sieweke, M. H., Doderlein, G., Graf, T. & Nerlov, C. Regulation of eosinophil-specific gene expression by a C/EBP-Ets complex and GATA-1. EMBO J. 17, 3669-3680 (1998).
26. Nerlov, C. & Ziff, E. B. CCAAT/enhancer binding protein-α amino acid motifs with dual TBP and TFIIB binding ability co-operate to activate transcription in both yeast and mammalian cells. EMBO J. 14, 4318-4328 (1995).
27. Kovacs, K. A., Steinmann, M., Magistretti, P. J., Halfon, O. & Cardinaux, J. R. CCAAT/enhancer-binding protein family members recruit the coactivator CREB-binding protein and trigger its phosphorylation. J. Biol. Chem. 278, 36959-36965 (2003).
28. Schwartz, C. et al. Recruitment of p300 by C/EBPβ triggers phosphorylation of p300 and modulates coactivator activity. EMBO J. 22, 882-892 (2003).
29. Pedersen, A., Kowenz-Leutz, E., Leutz, A. & Nerlov, C. Cooperation between C/EBPα TBP/TFIIB and SWI/SNF recruiting domains is required for adipocyte differentiation. Genes Dev. 15, 3208-3216 (2001).
30. Zhang, D. E. et al. CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF α2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol. Cell. Biol. 16, 1231-1240 (1996).
31. Yamaguchi, Y., Nishio, H., Kishi, K., Ackerman, S. J. & Suda, T. C. EBPβ and GATA-1 synergistically regulate activity of the eosinophil granule major basic protein promoter: implication for C/EBPβ activity in eosinophil gene expression. Blood 94, 1429-1439 (1999).
32. Reddy, V. A. et al. Granulocyte inducer C/EBPα inactivates the myeloid master regulator PU. 1: possible role in lineage commitment decisions. Blood 100, 483-490 (2002).
33. Umek, R. M., Friedman, A. D. & McKnight, S. L. CCAAT-enhancer binding protein: a component of a differentiation switch. Science 251, 288-292 (1991).
34. Muller, C. et al. Separation of C/EBPα-mediated proliferation arrest and differentiation pathways. Proc. Natl Acad. Sci. USA 96, 7276-7281 (1999).
35. Timchenko, N. A. et al. CCAAT/enhancer binding protein α regulates p21 protein and hepatocyte proliferation in newborn mice. Mol. Cell. Biol. 17, 7353-7361 (1997).
36. Wang, H. et al. C/EBPα arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol. Cell 8, 817-828 (2001).
37. Harbour, J. W. & Dean, D. C. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 14, 2393-2409 (2000).
38. Slomiany, B. A., D'Arigo, K. L., Kelly, M. M. & Kurtz, D. T. C/EBPα inhibits cell growth via direct repression of E2F-DP-mediated transcription. Mol. Cell. Biol. 20, 5986-5997 (2000). The first demonstration on of the capacity of C/EBPα to repress E2F-dependent transcription.
39. Porse, B. T. et al. E2F repression by C/EBPα is required for adipogenesis and granulopoiesis in vivo. Cell 107, 247-258 (2001). An in vivo demonstration of the coupling between cell-cycle control and terminal differentiation by C/EBPα.
40. Johansen, L. M. et al. c-Myc is a critical target for c/EBPα in granulopoiesis. Mol. Cell. Biol. 21, 3789-3806 (2001).
41. Hendricks-Taylor, L. R. & Darlington, G. J. Inhibition of cell proliferation by C/EBPα occurs in many cell types, does not require the presence of p53 or Rb, and is not affected by large T-antigen. Nucleic Acids Res. 23, 4726-4733 (1995).
42. Wang, Q. F., Cleaves, R., Kummalue, T., Nerlov, C. & Friedman, A. D. Cell cycle inhibition mediated by the outer surface of the C/EBPα basic region is required but not sufficient for granulopoiesis. Oncogene 22, 2548-2557 (2003).
43. Muller, C., Calkhoven, C. F., Sha, X. & Leutz, A. The CCAAT enhancer-binding protein α (C/EBPα) requires a SWI/SNF complex for proliferation arrest. J. Biol. Chem. 279, 7353-7358 (2004).
44. Zhang, H. S. & Dean, D. C. Rb-mediated chromatin structure regulation and transcriptional repression. Oncogene 20, 3134-3138 (2001).
45. Strom, D. K., Cleveland, J. L., Chellappan, S., Nip, J. & Hiebert, S. W. E2F-1 and E2F-3 are functionally distinct in their ability to promote myeloid cell cycle progression and block granulocyte differentiation. Cell Growth Differ. 9, 59-69 (1998).
46. Bjerregaard, M. D., Jurlander, J., Klausen, P., Borregaard, N. & Cowland, J. B. The in vivo profile of transcription factors during neutrophil differentiation in human bone marrow. Blood 101, 4322-4332 (2003).
47. Duprez, E., Wagner, K., Koch, H. & Tenen, D. G. C/EBPβ: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells. EMBO J. 22, 5806-5816 (2003).
48. Gery, S., Gombart, A. F., Fung, Y. K. & Koeffler, H. P. C/EBPε interacts with retinoblastoma and E2F1 during granulopoiesis. Blood 103, 828-835 (2003).
49. + mice: increased rate of myeloid proliferation and apoptosis. Leukemia 15, 103-111 (2001).
50. Jones, L. C. et al. Expression of C/EBPβ from the C/ebpα gene locus is sufficient for normal hematopoiesis in vivo. Blood 99, 2032-2036 (2002).
51. Truong, B. T. et al. CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia. Blood 101, 1141-1148 (2003).
52. Timchenko, N. A., Wilde, M., Nakanishi, M., Smith, J. R. & Darlingtong, G. J. CCAAT/enhancer-binding protein α (C/EBPα) inhibits cell proliferation through the p21 (WAF-1/CIP-1/SDI-1) protein. Genes Dev. 10, 804-815 (1996).
53. Timchenko, N. A., Wilde, M. & Darlington, G. J. C/EBPα regulates formation of S-phase-specific E2F-107 complexes in livers of newborn mice. Mol. Cell. Biol. 19, 2936-2945 (1999).
54. Iakova, P., Awad, S. S. & Timchenko, N. A. Aging reduces proliferative capacities of liver by switching pathways of C/EBPα growth arrest. Cell 113, 495-506 (2003).
55. Ross, S. E., Erickson, R. L., Hemati, N. & MacDougald, O. A. Glycogen synthase kinase 3 is an insulin-regulated C/EBPα kinase. Mol. Cell. Biol. 19, 8433-8441 (1999).
56. Behre, G. et al. Ras signaling enhances the activity of C/EBPα to induce granulocytic differentiation by phosphorylation of serine 248. J. Biol. Chem. 277, 26293-26299 (2002).
57. Weinstein, H. & Griffin, J. D. in Blood, Principles and Practice of Hematology (eds Handin, R. I., Lux, S. E. & Stossel, T. P.) 543-574 (J.B. Lippincott Company, Philadelphia, USA, 1995).